argenx SE 2022 AR2
The report highlights argenx SE's transition to a commercial-stage biopharmaceutical company in 2022, marked by the global launch of its first-in-class neonatal Fc receptor blocker, VYVGART, for generalized myasthenia gravis (gMG) in the U.S., Japan, and Europe. The company generated $400.7 million in global net product sales and expanded its pipeline to evaluate efgartigimod in ten autoimmune indications. Additionally, argenx advanced its complement inhibitor ARGX-117 into Phase 2 trials and initiated Phase 1 trials for ARGX-119. The company also expanded its global workforce to 843 employees to support its commercial and clinical growth.
Company: argenx SE
Sector: Manufacturing
Country: Netherlands
Year: 2022
Type: AR2
Pages: 382
Back to company
argenx SE
Annual Report
The report highlights argenx SE's transition to a commercial-stage biopharmaceutical company in 2022, marked by the global launch of its first-in-class neonatal Fc receptor blocker, VYVGART, for generalized myasthenia gravis (gMG) in the U.S., Japan, and Europe. The company generated $400.7 million in global net product sales and expanded its pipeline to evaluate efgartigimod in ten autoimmune indications. Additionally, argenx advanced its complement inhibitor ARGX-117 into Phase 2 trials and initiated Phase 1 trials for ARGX-119. The company also expanded its global workforce to 843 employees to support its commercial and clinical growth.
Sign in for free to access detailed sustainability data, reporting standards, and ESG metrics.
Document Details
Report Year
2022
Reporting Period
Jan 1, 2022 - Dec 31, 2022
Fiscal Year
2022
Type
Annual Report with Sustainability Disclosures
Language
English
Pages
File Size
Standards & Assurance
Assurance
Assurance Provider
Assurance Standard
ESG Data?Experimental: AI-extracted data, may contain inaccuracies
Women on Board
Women in Management
Employees